Omaha, NE – Streck offers a comprehensive flow cytometry product line that ensures the accuracy and reproducibility of all steps involved in the process of immunophenotyping by flow cytometry. Streck has new additions to the flow cytometry product line, CD-Chex CD103 Plus and CD-Chex TdT Plus, and they will be featured at the upcoming International Clinical Cytometry Meeting & Course (ICCS) in Denver, CO, Oct. 11-13, 2015.
CD-Chex CD103 Plus includes CD103, CD30, CD38, CD56, CD138 and cytoplasmic Lambda. The product is designed to represent abnormal peripheral blood leukocytes that possess surface antigens and intracellular antigens detectable with fluorescent monoclonal antibodies by flow cytometry.
CD-Chex TdT Plus evaluates intracellular and surface antigens, including TdT, CD1a, CD2, CD4, CD5, CD7, CD8, CD34 and cytoplasmic CD3, with monoclonal antibody binding by flow cytometry. When these cells are stained with fluorescent antibodies and analyzed by flow cytometry, they provide a reference value for abnormal cells found in certain types of hematopoietic neoplasms.
ICCS looks to help participants increase their knowledge of current tools and technologies available for patient sample analysis, better understand the accepted methodologies and benchmarks for patient sample analysis and diagnosis, and increase their competence in using analytical software applications. You can visit Streck at booth #13.
CD-Chex CD103 Plus and CD-Chex TdT Plus are For Research Use Only. Not for use in diagnostic procedures.
About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The companys pursuit of innovative solutions has produced an extensive list of patented products. Strecks core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit www.streck.com.